Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1;22(4):1019-1023.
doi: 10.31557/APJCP.2021.22.4.1019.

RET Protein Expression in Colorectal Cancer; An Immunohistochemical Assessment

Maryam Ashkboos  1 , Mehdi Nikbakht  1 , Giti Zarinfard  1 , Mitra Soleimani  1
Affiliations
Free PMC article

RET Protein Expression in Colorectal Cancer; An Immunohistochemical Assessment

Maryam Ashkboos et al. Asian Pac J Cancer Prev. .
Free PMC article

Abstract

Background: RET (rearranged during transfection) is a transmembrane receptor tyrosine kinase and a receptor for the GDNF-family ligands. It plays the role of a tumor suppressor in colorectal cancer. Therefore, it is expected that RET gene becomes downregulated in colorectal cancer (CRC). In this study, we evaluated immuno-histochemical expression of RET in CRC and assessed its correlation with some of the clinicopathological features to study the prognostic value in CRC.

Materials and methods: In total, 60 cases of colorectal cancer (CRC) from the patients who underwent surgical gastroenterology operations were randomly selected. The samples included one tumor-rich section per case and one adjacent tumor-free section as the normal control for that case. Then, immunohistochemistry (ICH) was performed for RET on all the samples and the expression of RET was analyzed. Furthermore, the correlation of RET with clinicopathological features including age, gender, location of the tumor, grade, and stage was evaluated.

Results: The expression of RET caused significant downregulation in cancer samples compared to the normal control ones (P = 0.002). This downregulation increased in correlation to both grade and metastasis to lymph nodes (P = 0.03 & 0.02 respectively). However, no correlation was found between the expression of RET and gender as well as location of the tumor.

Conclusion: RET may be considered as a protein marker in CRC detection and prognosis.

Keywords: CRC; ICH; MBD1; clinicopathological features.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A & B, The Expression of RET in Normal Sections Compared to C & D, CRC(Non-Mucinous) Stained Samples (100 & 400X Magnification). Brown stained cells are considered as positive cells for RET. B) Different intensity of positive stained cells for RET (1=non-stained, 2= mild, 3=moderate, 4=sever)
Figure 2
Figure 2
A & B, The Expression of RET in Normal Sections Compared to C & D, CRC (Mucinous) Stained Samples (100 & 400X Magnification). Brown stained cells are considered as positive cells for RET. B) Different intensity of positive stained cells for RET (1=non-stained, 2= mild, 3=moderate, 4=sever)
Figure 3
Figure 3
The Mean Expression of RET Protein in Cancer Samples Compared to Normal Samples
Figure 4
Figure 4
The Mean Expression of RET Protein in Cancer Samples Compared to Normal Samples Correlation to Tumor Type
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Plasma protein changes reflect colorectal cancer development and associated inflammation.
    Urbiola-Salvador V, Jabłońska A, Miroszewska D, Huang Q, Duzowska K, Drężek-Chyła K, Zdrenka M, Śrutek E, Szylberg Ł, Jankowski M, Bała D, Zegarski W, Nowikiewicz T, Makarewicz W, Adamczyk A, Ambicka A, Przewoźnik M, Harazin-Lechowicz A, Ryś J, Filipowicz N, Piotrowski A, Dumanski JP, Li B, Chen Z. Urbiola-Salvador V, et al. Front Oncol. 2023 May 9;13:1158261. doi: 10.3389/fonc.2023.1158261. eCollection 2023. Front Oncol. 2023. PMID: 37228491 Free PMC article.
  • RET signaling pathway and RET inhibitors in human cancer.
    Regua AT, Najjar M, Lo HW. Regua AT, et al. Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.

References

    1. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointestinal Cancer Res. 2012;5:19. - PMC - PubMed
    1. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers. 2013;5:676–713. - PMC - PubMed
    1. Fennell L, Dumenil T, Hartel G, et al. Genome scale epigenetic profiling reveals five distinct subtypes of colorectal cancer. Bio Rxiv. 2018;2018:397620.
    1. Grady WM. Context is everything for dependence receptors in colorectal cancer. Proc Nat Acad Sci U S A. 2013;110:2697–8. - PMC - PubMed
    1. Luo Y, Tsuchiya KD, Park DI F, et al. RET is a potential tumor suppressor gene in colorectal cancer. Oncogene. 2013;32:2037. - PMC - PubMed